Opendata, web and dolomites

EPIC SIGNED

Enabling Precision Immuno-oncology in Colorectal cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIC project word cloud

Explore the words cloud of the EPIC project. It provides you a very rough idea of what is the project "EPIC" about.

vitro    diagnosed    pillars    individual    algorithms    microsatellite    rewiring    organoids    reprogramming    combinations    generation    outcome    immunostimulatory    mechanistic    interrogation    content    modeling    chemotherapeutics    treatment    paradigm    combining    minority    experiments    immune    action    learning    tumor    networks    cancers    predicting    interference    profiling    sensitize    combination    quantitative    approved    cutting    survival    immuno    million    patient    immunity    cell    synergistic    benefits    immunomodulatory    cells    signaling    therapeutic    checkpoints    oncology    immunotherapy    metabolic    exception    determinants    integrates    checkpoint    blockers    infiltrating    data    worldwide    train    personalized    mechanisms    annually    conventional    somehow    independent    platform    recommendations    broaden    technologies    epic    drugs    refractory    attractive    instability    transforming    immunogenic    shown    agents    models    multidimensional    anticipated    lymphocytes    molecular    machine    clinical    systematic    throughput    urgent    immunological    silico    drug    paradoxical    validate    precision    edge    predictor    harness    cancer    tumors    patients    emphasis    therapy    perturbation    colorectal    crc    antitumor    resistance    interactions   

Project "EPIC" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE UNIVERSITAT INNSBRUCK 

Organization address
address: CHRISTOPH PROBST PLATZ 1
city: INNSBRUCK
postcode: 6020
website: www.i-med.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 2˙460˙500 €
 EC max contribution 2˙460˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAT INNSBRUCK AT (INNSBRUCK) coordinator 2˙460˙500.00

Map

 Project objective

Immunotherapy with checkpoints blockers is transforming the treatment of advanced cancers. Colorectal cancer (CRC), a cancer with 1.4 million new cases diagnosed annually worldwide, is refractory to immunotherapy (with the exception of a minority of tumors with microsatellite instability). This is somehow paradoxical as CRC is a cancer for which we have shown that it is under immunological control and that tumor infiltrating lymphocytes represent a strong independent predictor of survival. Thus, there is an urgent need to broaden the clinical benefits of immune checkpoint blockers to CRC by combining agents with synergistic mechanisms of action. An attractive approach to sensitize tumors to immunotherapy is to harness immunogenic effects induced by approved conventional or targeted agents. Here I propose a new paradigm to identify molecular determinants of resistance to immunotherapy and develop personalized in silico and in vitro models for predicting response to combination therapy in CRC. The EPIC concept is based on three pillars: 1) emphasis on antitumor T cell activity; 2) systematic interrogation of tumor-immune cell interactions using data-driven modeling and knowledge-based mechanistic modeling, and 3) generation of key quantitative data to train and validate algorithms using perturbation experiments with patient-derived tumor organoids and cutting-edge technologies for multidimensional profiling. We will investigate three immunomodulatory processes: 1) immunostimulatory effects of chemotherapeutics, 2) rewiring of signaling networks induced by targeted drugs and their interference with immunity, and 3) metabolic reprogramming of T cells to enhance antitumor immunity. The anticipated outcome of EPIC is a precision immuno-oncology platform that integrates tumor organoids with high-throughput and high-content data for testing drug combinations, and machine learning for making therapeutic recommendations for individual patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

EnTER (2020)

Enhanced Mass Transport in Electrochemical Systems for Renewable Fuels and Clean Water

Read More  

CerQuS (2019)

Certified Quantum Security

Read More  

PLANTGROWTH (2019)

Exploiting genome replication to design improved plant growth strategies

Read More